TY - JOUR
T1 - High-dose rifapentine with moxifloxacin for pulmonary tuberculosis
AU - Jindani, Amina
AU - Harrison, Thomas S.
AU - Nunn, Andrew J.
AU - Phillips, Patrick P J
AU - Churchyard, Gavin J.
AU - Charalambous, Salome
AU - Hatherill, Mark
AU - Geldenhuys, Hennie
AU - McIlleron, Helen M.
AU - Zvada, Simbarashe P.
AU - Mungofa, Stanley
AU - Shah, Nasir A.
AU - Zizhou, Simukai
AU - Magweta, Lloyd
AU - Shepherd, James
AU - Nyirenda, Sambayawo
AU - Van Dijk, Janneke H.
AU - Clouting, Heather E.
AU - Coleman, David
AU - Bateson, Anna L E
AU - McHugh, Timothy D.
AU - Butcher, Philip D.
AU - Mitchison, Denny A.
PY - 2014/10/23
Y1 - 2014/10/23
N2 - METHODS We randomly assigned patients with newly diagnosed, smear-positive, drug-sensitive tuberculosis to one of three regimens: a control regimen that included 2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed by 4 months of daily isoniazid and rifampicin; a 4-month regimen in which the isoniazid in the control regimen was replaced by moxifloxacin administered daily for 2 months followed by moxifloxacin and 900 mg of rifapentine administered twice weekly for 2 months; or a 6-month regimen in which isoniazid was replaced by daily moxifloxacin for 2 months followed by one weekly dose of both moxifloxacin and 1200 mg of rifapentine for 4 months. Sputum specimens were examined on microscopy and after culture at regular intervals. The primary end point was a composite treatment failure and relapse, with noninferiority based on a margin of 6 percentage points and 90% confidence intervals.RESULTS We enrolled a total of 827 patients from South Africa, Zimbabwe, Botswana, and Zambia; 28% of patients were coinfected with the human immunodefiency virus. In the per-protocol analysis, the proportion of patients with an unfavorable response was 4.9% in the control group, 3.2% in the 6-month group (adjusted difference from control, -1.8 percentage points; 90% confidence interval [CI], -6.1 to 2.4), and 18.2% in the 4-month group (adjusted difference from control, 13.6 percentage points; 90% CI, 8.1 to 19.1). In the modified intention-to-treat analysis these proportions were 14.4% in the control group, 13.7% in the 6-month group (adjusted difference from control, 0.4 percentage points; 90% CI, -4.7 to 5.6), and 26.9% in the 4-month group (adjusted difference from control, 13.1 percentage points; 90% CI, 6.8 to 19.4).CONCLUSIONS The 6-month regimen that included weekly administration of high-dose rifapentine and moxifloxacin was as effective as the control regimen. The 4-month regimen was not noninferior to the control regimen. (Funded by the European and Developing Countries Clinical Trials Partnership and the Wellcome Trust; RIFAQUIN Current Controlled Trials number, ISRCTN44153044.).BACKGROUND Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed.
AB - METHODS We randomly assigned patients with newly diagnosed, smear-positive, drug-sensitive tuberculosis to one of three regimens: a control regimen that included 2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed by 4 months of daily isoniazid and rifampicin; a 4-month regimen in which the isoniazid in the control regimen was replaced by moxifloxacin administered daily for 2 months followed by moxifloxacin and 900 mg of rifapentine administered twice weekly for 2 months; or a 6-month regimen in which isoniazid was replaced by daily moxifloxacin for 2 months followed by one weekly dose of both moxifloxacin and 1200 mg of rifapentine for 4 months. Sputum specimens were examined on microscopy and after culture at regular intervals. The primary end point was a composite treatment failure and relapse, with noninferiority based on a margin of 6 percentage points and 90% confidence intervals.RESULTS We enrolled a total of 827 patients from South Africa, Zimbabwe, Botswana, and Zambia; 28% of patients were coinfected with the human immunodefiency virus. In the per-protocol analysis, the proportion of patients with an unfavorable response was 4.9% in the control group, 3.2% in the 6-month group (adjusted difference from control, -1.8 percentage points; 90% confidence interval [CI], -6.1 to 2.4), and 18.2% in the 4-month group (adjusted difference from control, 13.6 percentage points; 90% CI, 8.1 to 19.1). In the modified intention-to-treat analysis these proportions were 14.4% in the control group, 13.7% in the 6-month group (adjusted difference from control, 0.4 percentage points; 90% CI, -4.7 to 5.6), and 26.9% in the 4-month group (adjusted difference from control, 13.1 percentage points; 90% CI, 6.8 to 19.4).CONCLUSIONS The 6-month regimen that included weekly administration of high-dose rifapentine and moxifloxacin was as effective as the control regimen. The 4-month regimen was not noninferior to the control regimen. (Funded by the European and Developing Countries Clinical Trials Partnership and the Wellcome Trust; RIFAQUIN Current Controlled Trials number, ISRCTN44153044.).BACKGROUND Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed.
UR - http://www.scopus.com/inward/record.url?scp=84908139920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908139920&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1314210
DO - 10.1056/NEJMoa1314210
M3 - Article
C2 - 25337749
AN - SCOPUS:84908139920
SN - 0028-4793
VL - 371
SP - 1599
EP - 1608
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 17
ER -